In this study, a high Siglec15 expression level was associated with an adverse prognosis and shortened recurrence, consistent with previous reports on many other tumors, including lung cancer (20), pancreatic ductal adenocarcinoma (21), breast cancer, thyroid carcinoma, sarcoma, and uterine corpus endometrial carcinoma (8). Here, SIGLEC15 is linked to pancreatic ductal adenocarcinoma.